Skip to main content
SpringerLink
Log in

Fc-Gamma-Receptor IIIa Polymorphism and Gene Expression Profile Do Not Predict the Prognosis in Diffuse Large B-cell Lymphoma Treated with R-CHOP Protocol

  • Research
  • Published:
Pathology & Oncology Research

Abstract

The addition of rituximab to conventional chemotherapy has significantly improved the treatment outcome in diffuse large B-cell lymphoma. However, differences in treatment response and survival data can be observed independently from the International Prognostic Index scores. The current study evaluated the impact of Fc-gamma-receptor IIIa polymorphism and gene expression profile on the response of DLBCL patients to R-CHOP therapy as well as on their survival results. Fifty-one patients were involved, thirty-two females, nineteen males, their median age was 53.1 years. The FCGR3A polymorphism at the 158. amino acid position determined with PCR method showed the following results: VV: 12 cases (23.5%), VF: 29 cases (56.8%) and FF: 10 cases (19.6%), respectively. There was no significant difference between the treatment responses of the three groups. The event-free survival data were less favorable in the F-allele carriers than in V/V homozygous patients, but without any significancy, and the overall survival curves were almost the same. As for the gene expression profile, 20 patients’ biopsy specimens showed germinal center and 31 showed non-germinal center characteristics. Treatment results did not differ from each other in the two groups. Both the event-free and the overall survival data were more favorable in the GC group, however the differences were not significant. Our results contest the predictive value of Fc-gamma-receptor IIIa polymorphism and gene expression profile in diffuse large B-cell lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

ABC:

Activated B-cell

ADCC:

Antibody dependent cellular cytotoxicity

bp:

Base pair

CD:

Cluster designation

DLBCL:

Diffuse large B-cell lymphoma

DNA:

Desoxy ribonucleic acid

EFS:

Event-free survival

F:

Phenylalanine

FCGR3A:

Fc-gamma-receptor IIIa

GC:

Germinal center

IPI:

International prognostic index

mRNA:

Messenger ribonucleic acid

NK:

Natural killer

OS:

Overall survival

PCR:

Polymerase chain reactiom

R-CHOP:

Rituximab, cyclophosphamide, H-daunorubicine, oncovin, prednisolone

V:

Valine

References

  1. Coiffier B, Reyes F, Groupe d’Etude des Lymphomes de l’Adulte (2005) Best treatment of agressive non-Hodgkin’s lymphoma: a French perspective. Oncology (Williston Park) 19:7–15

    Google Scholar 

  2. Nitsu N (2010) Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol 92:231–237

    Article  Google Scholar 

  3. Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861

    Article  PubMed  CAS  Google Scholar 

  4. Lossos IS, Morgensztern D (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24:995–1007

    Article  PubMed  CAS  Google Scholar 

  5. Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644–1652

    PubMed  CAS  Google Scholar 

  6. Villamor N, Montserrat E, Colomer D (2003) Mechanism of action and resistance to monoclonal antibody therapy. Sem Oncol 30:424–433

    Article  CAS  Google Scholar 

  7. Koene HR, Kleijer M, Algra J et al (1997) FcgRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell FcgRIIIa, idependently of the FcgRIIIa-48 L/R/H phenotype. Blood 1997:1109–1114

    Google Scholar 

  8. Hatjiharissi E, Lian X, Santos DD et al (2007) Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcgRIIIa-158 V/V and V/F polymorphism. Blood 110:2561–2564

    Article  PubMed  CAS  Google Scholar 

  9. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511

    Article  PubMed  CAS  Google Scholar 

  10. Morgenszter D, Martin MG, Lossos IS (2007) Gene expression profiling in diffuse large B-cell lymphoma. Leuk Lymph 48:669–682

    Article  Google Scholar 

  11. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282

    Article  PubMed  CAS  Google Scholar 

  12. Cartron G, Watier H, Golay J et al (2004) From the bench to bedside: ways to improve rituximab efficacy. Blood 104:2635–2642

    Article  PubMed  CAS  Google Scholar 

  13. Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99:754–758

    Article  PubMed  CAS  Google Scholar 

  14. Treon SP, Hansen M, Branagan AR et al (2005) Polymorphisms in FcgRIIIa (CD16) receptor expression are associated with clinical response to rituximab in Waldenström’s macroglobulinaemia. J Clin Oncol 23:474–481

    Article  PubMed  CAS  Google Scholar 

  15. Farag SS, Flinn IW, Modali R et al (2004) Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukaemia. Blood 103:1472–1474

    Article  PubMed  CAS  Google Scholar 

  16. Carlotti E, Palumbo GA, Oldani E et al (2007) Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab. Hematologica 92:1127–1130

    Article  CAS  Google Scholar 

  17. Kim DW, Jung HD, Kim JG et al (2006) FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108:2720–2725

    Article  PubMed  CAS  Google Scholar 

  18. Sjö LD, Poulsen CB, Hansen M et al (2007) Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol 79:501–507

    Article  PubMed  Google Scholar 

  19. Nyman H, Adde M, Karjalainen-Lindsberg ML et al (2007) Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109:4930–4935

    Article  PubMed  CAS  Google Scholar 

  20. Fu K, Weisenberger DD, Choi W et al (2008) Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 26:4587–4594

    Article  PubMed  CAS  Google Scholar 

  21. Mounier N, Briere J, Gisselbrecht C et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279–4284

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by the MECENATURA grant of the University of Debrecen.

Author information

Authors and Affiliations

  1. 3rd Department of Medicine, Institute for Medicine, Medical and Health Science Center, University of Debrecen, Móricz Zs. 22., 4032, Debrecen, Hungary

    László Váróczy, Lajos Gergely & Árpád Illés

  2. Regional Laboratory for Immunology, Medical and Health Science Center, University of Debrecen, Móricz Zs. 22., 4032, Debrecen, Hungary

    Erika Zilahi, Ágnes Gyetvai & Sándor Sipka

  3. Department of Pathology, University of Pécs, Pécs, Hungary

    Béla Kajtár

Authors
  1. László Váróczy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erika Zilahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ágnes Gyetvai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Béla Kajtár
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lajos Gergely
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sándor Sipka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Árpád Illés
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to László Váróczy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Váróczy, L., Zilahi, E., Gyetvai, Á. et al. Fc-Gamma-Receptor IIIa Polymorphism and Gene Expression Profile Do Not Predict the Prognosis in Diffuse Large B-cell Lymphoma Treated with R-CHOP Protocol. Pathol. Oncol. Res. 18, 43–48 (2012). https://doi.org/10.1007/s12253-011-9414-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-011-9414-7

Keywords

Search

Navigation